drugset / Trial / NCT00869778

Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B

NCT00869778

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose is to evaluate efficacy and safety of therapeutic Hepatitis B Virus(HBV) vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal dosing schedule.

Timeline

Start
2009-04
Primary completion
2011-11
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject εPA-44 Vaccine 600 ug Subcutaneous
Subject εPA-44 Vaccine 900 ug Subcutaneous